<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1820">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04328012</url>
  </required_header>
  <id_info>
    <org_study_id>1581969</org_study_id>
    <nct_id>NCT04328012</nct_id>
  </id_info>
  <brief_title>COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19</brief_title>
  <acronym>COVIDMED</acronym>
  <official_title>Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bassett Healthcare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Reid Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Goshen Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bassett Healthcare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a randomized, double-blind, placebo-controlled, multi-center, Phase 2-like,&#xD;
      investigator-directed trial, hospitalized adult patients with laboratory confirmed SARS-CoV-2&#xD;
      infection meeting inclusion and exclusion criteria, will be provided information on the&#xD;
      trial, offered enrollment, and if informed consent provided, enrolled randomly in a 2:1 ratio&#xD;
      to one of two groups: Group 1 standard care and losartan or Group 2 standard care and&#xD;
      placebo. Patients will be followed for up to 60 days, with data collected to quantify the&#xD;
      NCOSS over time (the primary objective), and for the trial's secondary objectives (see&#xD;
      outcome measurements below).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although a number of therapeutics have been utilized by clinicians to treat hospitalized&#xD;
      patients with COVID-19, none were systematically evaluated in clinical trials at the time of&#xD;
      the outset of this RCT (COVID MED). Since then, dexamethasone has been shown to decrease&#xD;
      mortality and remdesivir to possibly decrease hospital LOS in the RECOVERY and ACTT-II trials&#xD;
      and others. The initial iteration of this protocol included 4 arms, hydroxychloroquine,&#xD;
      lopinavir/ritonavir, losartan, and placebo based on suggestive efficacy and safety and&#xD;
      widespread empiric use. The current iteration of COVID MED includes two arms, standard of&#xD;
      care and losartan vs. standard of care and placebo.&#xD;
&#xD;
      Hydroxychloroquine was initially included in COVID MED based on suggestive in vitro, animal&#xD;
      preclinical, and early RCT data, and widespread empiric use in hospitalized patients with&#xD;
      COVID-19. Lopinavir/ritonavir, an antiretroviral medication, showed equivocal and possibly&#xD;
      positive efficacy and safety in an early pandemic Chinese RCT published in NEJM. After public&#xD;
      release and eventual publication of the negative results for hydroxychloroquine and then&#xD;
      lopinavir/ritonavir initially from the RECOVERY trial and then others, enrollment in COVID&#xD;
      MED in these two arms was halted and then discontinued permanently. Data from subjects&#xD;
      enrolled in the hydroxychloroquine arm are being incorporated into a pooled analysis of RCTs&#xD;
      by the Trial Innovation Network.&#xD;
&#xD;
      Losartan, an angiotensin II receptor blocker (ARB), has theoretical benefit as SARSCoV-2&#xD;
      appears to bind to lung tissue via Angiotensin-Converting Enzyme 2 (ACE-2) receptors which&#xD;
      might be inhibited by ARBs; other potential benefits have been hypothesized as well. Since&#xD;
      the initial iteration of this protocol, observational studies have shown that patients&#xD;
      already taking ACEi/ARB medications do not have adverse outcome when these drugs are&#xD;
      continued in hospitalized COVID-19 patients. These data have reinforced continuation of the&#xD;
      losartan vs. placebo arms of this RCT which are ongoing.&#xD;
&#xD;
      This pragmatic adaptive trial continues to compare outcome in hospitalized COVID-19 patients&#xD;
      treated with standard of care and losartan vs. standard of care and placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, double blind, placebo controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)</measure>
    <time_frame>60 days</time_frame>
    <description>difference in NCOSS scores between the different treatment groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay (LOS)</measure>
    <time_frame>60 days</time_frame>
    <description>difference in the total inpatient LOS between the three treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit level LOS</measure>
    <time_frame>60 days</time_frame>
    <description>difference in the total ICU level care LOS between the three treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>60 days</time_frame>
    <description>difference in length of use of mechanical ventilation between the three treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>60 days</time_frame>
    <description>difference in all cause mortality between the four treatment groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>losartan 25 mg po QD X 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo QD X 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>administered 14 days</description>
    <arm_group_label>Losartan</arm_group_label>
    <other_name>Cozaar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>administered 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Hospitalized patient&#xD;
&#xD;
          2. Age &gt;= 18 years&#xD;
&#xD;
          3. Able to ingest oral medication or be administered medication via gastric tube or&#xD;
             equivalent&#xD;
&#xD;
          4. Laboratory confirmation of SARS-CoV-2 infection within 1 week prior to randomization&#xD;
&#xD;
          5. Randomization within 72 hr of hospital admission&#xD;
&#xD;
          6. Negative pregnancy test for reproductive age women&#xD;
&#xD;
          7. Patient or LAR able to provide informed consent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Allergy or intolerance to losartan or other ARBs&#xD;
&#xD;
          2. Already taking ACE or ARB (within 1 month)&#xD;
&#xD;
          3. Hypotension at time of enrollment (SBP &lt; 100 mm Hg)&#xD;
&#xD;
          4. Hyperkalemia (K &gt;/= 5.0 at time of screening or history of hyperkalemia)&#xD;
&#xD;
          5. Severe renal dysfunction (estimated GFR &lt; 30 ml/min at time of screening or history&#xD;
             advanced renal disease)&#xD;
&#xD;
          6. Severe volume depletion or acute kidney injury (AKI) at time of enrollment&#xD;
&#xD;
          7. Known cirrhotic ascites&#xD;
&#xD;
          8. Known severe aortic or mitral valve stenosis&#xD;
&#xD;
          9. Known unstented renal artery stenosis&#xD;
&#xD;
         10. Co-administration with certain drugs due to CYP3A interactions if taken in &lt; 24 hr&#xD;
&#xD;
         11. Severe hepatic insufficiency (LFTs &gt; 5 times the upper limit of normal or known ESLD&#xD;
             or cirrhosis)&#xD;
&#xD;
         12. Nausea/vomiting or aspiration risk precluding oral medications unless can be given by&#xD;
             gastric tube&#xD;
&#xD;
         13. Pregnancy or breast feeding&#xD;
&#xD;
         14. Absence of dependable contraception in reproductive age women&#xD;
&#xD;
         15. Inability to obtain or declined informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Freilich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bassett Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Victory, RN</last_name>
    <phone>6075476965</phone>
    <email>jennifer.victory@bassett.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Freilich, MD</last_name>
    <phone>6075474586</phone>
    <email>daniel.freilich@bassett.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bassett Medical Center</name>
      <address>
        <city>Cooperstown</city>
        <state>New York</state>
        <zip>13326</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Pullyblank, RN, MS</last_name>
      <phone>607-547-6711</phone>
      <email>kristin.pullyblank@bassett.org</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Victory, RN</last_name>
      <phone>6075476965</phone>
      <phone_ext>Victory</phone_ext>
      <email>jennifer.victory@bassett.org</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Freilich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 27, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bassett Healthcare</investigator_affiliation>
    <investigator_full_name>Daniel Freilich, MD</investigator_full_name>
    <investigator_title>attending physician - hospitalist</investigator_title>
  </responsible_party>
  <keyword>COVID</keyword>
  <keyword>COVID-19</keyword>
  <keyword>coronavirus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

